PLUS THERAPEUTICS INC PSTV 深 滬
已收盤 01-09 16:00:00 美东时间
0.5552
-0.030
-5.11%
華盛通- 最 高0.5985
- 今 開0.59
- 成交量 685.14万股
- 最 低 0.555
- 昨 收 0.5851
- 總市值 7606.24万
- 52周最高 2.3099
- 市盈率 靜 --
- 換手率 5.00%
- 52周最低 0.1634
- 委 比 99.90%
- 總股本 1.37亿
- 歷史最高 343.35
- 量 比 2.06
- 振 幅 7.43%
- 歷史最低 0.1634
- 每 手 1
- 風險率 0.31%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
Plus Therapeutics Completes Type B Meeting With FDA Over Next Steps On REYOBIQ Pivotal Study Strategy For Leptomeningeal Metastases
Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers,
01-08 20:35
Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases
Plus Therapeutics, Inc. announces completion of a Type B meeting with the FDA on the pivotal trial strategy for REYOBIQ in treating leptomeningeal metastases (LM). Key outcomes include FDA feedback on accelerated approval, study endpoints, trial design, and population. The company aims to incorporate FDA feedback into its current dose optimization trial and plans to advance manufacturing for a potential pivotal trial by late 2026. REYOBIQ, a radi...
01-08 12:30
Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants
Plus Therapeutics, Inc. subsidiary CNSide Diagnostics announced the hiring of Prem Gurnani as Senior Director of Lab Operations and Elaine Luckey as Director of Quality & Regulatory Affairs. Both received stock options and RSUs as part of their compensation. The company expects these hires to enhance its capabilities in addressing the CNS cancer diagnostics market.
2025-12-09 12:30
美股大行评级 | 超配！BETA、BillionToOne获多家机构首予评级；摩根大通上调阿斯麦目标价升至1275美元
今日重点评级关注：RBC Capital：上调Neumora Therapeutics评级至"跑赢大市"，目标价从4美元升至7美元；HC Wainwright & Co.：维持ProMIS Neurosciences"买入"评级，目标价从4美元升至18美元
2025-12-02 09:50
Plus Therapeutics To Present ReSPECT Phase 1 Dose Escalation Study Results For Leptomeningeal Metastases At 2025 SABCS
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers,
2025-12-01 20:38
美股大行评级 | 最高130美元！11家大行集体上调沃尔玛目标价；戴康工业、Gap、罗斯百货等均或多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Fractyl Health"买入"评级，目标价从6美元升至8美元；HC Wainwright & Co.：维持MediWound"买入"评级，目标价从31美元升至36美元
2025-11-24 11:23
Plus Therapeutics' CNSide Diagnostics Signs National Agreement With Humana To Provide CNSide Cerebrospinal Fluid Tumor Cell Enumeration Laboratory Developed Test
CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), announced today that it has signed a national agreement with Humana, Inc. (NYSE:HUM),
2025-11-20 20:34
Plus Therapeutics granted 180-day to regain compliance with Nasdaq
Plus Therapeutics (PSTV) announced on Monday that it has received an additional 180-day extension period from the Nasdaq to regain compliance with the $1.00 minimum bid price requirement as per Nasdaq...
2025-11-17 21:06
Plus Therapeutics Gains Nasdaq Extension for Compliance
Plus Therapeutics ( ($PSTV) ) has provided an announcement. On November 17, 202...
2025-11-17 20:58
